Citi analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $207.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Ascendis Pharma (ASND) PT Lowered to $180 at OppenheimerNovember 15, 2024 6:21 AM Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.November 14, 2024 5:47 PM Form 6-K Ascendis Pharma A/S For: Nov 14November 14, 2024 4:20 PM Form 6-K Ascendis Pharma A/S For: Sep 30November 14, 2024 4:16 PM Ascendis Pharma (ASND) Misses Q3 EPS by 18c, provides outlookNovember 14, 2024 4:04 PM Ascendis Pharma Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 4:01 PM Form SC 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLCNovember 14, 2024 2:57 PM Form SC 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc.November 14, 2024 1:30 PM Form SC 13G/A Ascendis Pharma A/S Filed by: Avoro Capital Advisors LLCNovember 14, 2024 9:31 AM Form 6-K Ascendis Pharma A/S For: Nov 13November 13, 2024 4:02 PM